-
1. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther. 18：969-78, 2011.
Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC.
-
2. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 12：301-9, 2009.
Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC.
-
3. Nestin is an independent predictor of cancer-specific survival after radical cystectomy in patients with urothelial carcinoma of the bladder. PLoS One. 9：1-6, 2014.
Tabata K, Matsumoto K, Minami S, Ishii D, Nishi M, Fujita T, Saegusa M, Sato Y, Iwamura M.
-
4. Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med. 2012：1-6, 2012.
Tabata K, Niibe Y, Satoh T, Tsumura H, Ikeda M, Minamida S, Fujita T, Ishii D, Iwamura M, Hayakawa K, Baba S.
-
5. ハイリスク前立腺癌に対する術前8ヵ月ネオアジュバント内分泌療法の有用性に関する検討．日本泌尿器科学会雑誌， 97：712〜718, 2006.
田畑健一，佐藤威文，松本和将，藤田哲夫，入江 啓，岩村正嗣, 柳澤信之, 松田大介，村本将俊，門脇和臣，須山一穂，庄司清志，黄英茂，川上達央，岡安勲，頴川晋，馬場志郎
-
6. ロボット支援腹腔鏡下前立腺全摘除術の手術成績 腹腔鏡下根治的前立腺全摘除術との比較. 北里医学 45：103-107, 2015.
田畑 健一,佐藤 威文,津村 秀康,平山 貴博,西 盛宏,藤田 哲夫,松本 和将,岩村 正嗣
-
7. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk+ ganciclovir gene therapy for prostate cancer. Asian J Urol. 8：280-288. 2021.
Yanagisawa N, Satoh T, Tabata KI, Tsumura H, Nasu Y, Watanabe M, Thompson TC, Okayasu I, Murakumo Y, Baba S, Iwamura M.
-
8. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. BMC Cancer. 20：919-926, 2020.
Kawahara T, Kato M, Tabata K, Kojima I, Yamada H, Kamihira O, Tsumura H, Iwamura M, Uemura H, Miyoshi Y.
-
9. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 38：395-405, 2020.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS.
-
10. Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients. Jpn J Radiol. 38：993-996, 2020.
Hayakawa T, Tabata KI, Tsumura H, Kawakami S, Katakura T, Hashimoto M, Watanabe Y, Iwamura M, Hasegawa T, Ishiyama H.
-
11. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol. 17：71-81, 2022.
Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H.
-
12. Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy. Int J Urol. May 25. Online ahead of print, 2022.
Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T; Japanese Urological Oncology Group.
-
13. Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden. Int J Urol. 29：398-405, 2022.
Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata KI, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H; Japanese Urological Oncology Group (JUOG).
-
14. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. Int J Clin Oncol. 26：578-590, 2021.
Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, Smith M, Shore N, Tammela T, Tabata KI, Matsubara N, Iinuma M, Uemura H, Oya M, Momma T, Kawakita M, Fukasawa S, Kobayashi T, Kuss I, Le Berre MA, Snapir A, Sarapohja T, Suzuki K.
-
15. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci. 112：3616-3626, 2021.
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group.
-
16. A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-na ve prostate cancer. BJUI Compass. 2：105-114, 2020.
Miyoshi Y, Yasui M, Yoneyama S, Kawahara T, Nakagami Y, Ohno Y, Iizuka J, Tanabe K, Hashimoto Y, Tsumura H, Tabata KI, Iwamura M, Yano A, Kawakami S, Uemura H.
-
17. Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. BJUI Compass. 1：165-173, 2020.
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata KI, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T; Japanese Urological Oncology Group.
-
18. Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naive Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study. Biomed Res Int. 2020：1-6, 2020.
Kawahara T, Yoneyama S, Ohno Y, Iizuka J, Hashimoto Y, Tsumura H, Tabata KI, Nakagami Y, Tanabe K, Iwamura M, Uemura H, Miyoshi Y.
-
19. Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy. Prostate. 77：1520-1527, 2017.
Tsumura H, Ishiyama H, Tabata KI, Katsumata H, Kobayashi M, Ikeda M, Kurosaka S, Fujita T, Kitano M, Satoh T, Yanagisawa N, Hayakawa K, Iwamura M.
-
20. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 15：1073-1080, 2017.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S.
-
21. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 15：320-325, 2017.
Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
-
22. Abiraterone acetate after progression with enzalutamide in chemotherapy-na ve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. BMC Res Notes. 9：471-7. 2016.
Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.
-
23. Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS. J Contemp Brachytherapy. 8：7-16, 2016.
Ishiyama H, Sekiguchi A, Satoh T, Tsumura H, Takenaka K, Kawakami S, Tabata K, Kobayashi K, Iwamura M, Hayakawa K.
-
24. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. J Contemp Brachytherapy. 8：95-103, 2016.
Tsumura H, Satoh T, Ishiyama H, Tabata K, Komori S, Sekiguchi A, Ikeda M, Kurosaka S, Fujita T, Kitano M, Hayakawa K, Iwamura M.
-
25. Laparoscopic Retroperitoneal Nephroureterectomy is a Safe and Adherent Modality for Obese Patients with Upper Urinary Tract Urothelial Carcinoma. Asian Pac J Cancer Prev. 16：3223-7. 2015.
Matsumoto K, Hirayama T, Kobayashi K, Hirano S, Nishi M, Ishii D, Tabata K, Fujita T, Iwamura M.
-
26. Enhanced central memory cluster of differentiation 8+ and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. Mol Clin Oncol. 3：515-521, 2015.
Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, Thompson TC, Obata F.
-
27. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. Jpn J Clin Oncol. 45：774-9, 2015.
Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
-
28. Laparoscopic adrenalectomy for metastatic adrenal tumor. Asian J Endosc Surg. 7：43-7, 2014.
Hirayama T, Fujita T, Koguchi D, Nishi M, Kurosaka S, Tsumura H, Tabata K, Iwamura M.
-
29. Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. Biomed Pharmacother. 68：71-7, 2014.
Takahashi R, Amano H, Satoh T, Tabata K, Ikeda M, Kitasato H, Akira S, Iwamura M, Majima M.
-
30. 125Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up. J Radiat Res. 55：328-33, 2014.
Sekiguchi A1, Ishiyama H, Satoh T, Tabata K, Komori S, Tsumura H, Kawakami S, Soda I, Iwamura M, Hayakawa K.
-
1. 田畑 健一、【前立腺癌(第2版)-基礎・臨床研究のアップデート-】基礎 進行前立腺癌に対する新戦略 分子標的治療、日本臨床社、2：165-169, 2011.
-
2. 田畑 健一, 佐々木治一郎、『入門腫瘍内科学（改訂第２版）』、篠原出版新社、各論 前立腺がん. 2：209-212, 2015.
-
3. 田畑 健一, 【新腎・泌尿器癌(下)-基礎・臨床研究の進歩-】精巣癌 精巣癌の治療 化学療法 導入化学療法. 日本臨床. 75： 430-434, 2017.
-
4. 田畑 健一, 佐藤威文, 馬場志郎、『前立腺がんの分子標的治療』、メディカルレビュー社、6：42-49, 2008.
-
5. 田畑 健一、『化学療法の実際と問題点』、前立腺癌の診療ナビゲーション、臨床泌尿器科 4：214-218, 2014.
-
6. 田畑 健一.ASCO2014のトピックス〜癌治療の最前線〜 前立腺がん. Medicament News 2014.
-
7. 田畑 健一.ASCO2014前立腺がん 会員聴講レポート. CareNet 2014.
-
8. 田畑 健一, 藤田 哲夫, 佐藤 威文, 津村 秀康, 岩村 正嗣, 【前立腺癌の診断および手術におけるupdate】前立腺摘除 腹腔鏡下前立腺全摘除術のコツ. 泌尿器外科 27：311-315, 2014.
-
9. 田畑 健一, 岩村 正嗣, 【こうしてます!内視鏡外科手術をサポートする臨床工学技士の役割】内視鏡外科手術における医療安全からみた臨床工学技士の役割. Clinical Engineering 27：13-19, 2015.
-
10. 萩原 正博(北里大学 医学部泌尿器科), 佐藤 威文, 田畑 健一, 津村 秀康, 稲野 寛, 厚田 幸一郎, 岩村 正嗣, 【前立腺癌 がん・合併症・有害事象での薬物治療戦略を総まとめ】新たに登場した医薬品のノウハウとピットフォール アビラテロン. 薬局, 67：3034-3039, 2016.
-
11. 田畑 健一, 岩村 正嗣, 【まるごと泌尿器がんの化学療法・分子標的療法・免疫療法】去勢抵抗性前立腺がん 新規ホルモン剤(アビラテロン・エンザルタミド)の副作用コントロール. Uro-Lo: 泌尿器Care & Cure 22：613-618, 2017.
-
12. 田畑 健一, 【まるごと 基礎〜最新まですべてがわかる!前立腺がん Up-to-date】前立腺がんの手術 ロボット支援手術および腹腔鏡下手術. Uro-Lo: 泌尿器Care & Cure, 24：42-44, 2019.
-
13. 田畑 健一, 前立腺癌診療に関する最新コンセンサス -APCCC 2019を受けて-. 3：7-14, 2020.
-
14. 田畑 健一, 【前立腺癌の診療ナビゲーション-わかりやすく丁寧に!】前立腺癌の治療と問題点 《化学療法》 化学療法の実際と問題点 化学療法の適応,実際,注意点について教えてください. 臨床泌尿器科 68：214-218, 2014.
-
15. 田畑 健一、藤田哲夫、佐藤威文、津村秀康、岩村正嗣、『腹腔鏡下前立腺全摘除術のコツ』 泌尿器外科 27：311-315, 2014.
-
16. 田畑 健一, 【ハイリスク前立腺癌を深掘りする-その変遷とM0 CRPCの最新治療】HNPC治療の現状と課題 HNPCに対するドセタキセルによる治療. 臨床泌尿器科. 73：552-555, 2019.
-
17. 田畑 健一, M1前立腺癌の局所療法の是非を問う M1前立腺癌の局所療法 是とする立場から. 泌尿器外科 32：688-689, 2019.
-
18. 田畑 健一, 津村 秀康, 岩村 正嗣 【オリゴ転移・オリゴ再発前立腺癌を巡る諸問題】転移巣標的局所治療. 泌尿器外科 33：953-958, 2020.
-
19. 田畑 健一 【進化する去勢抵抗性前立腺がんの診断と治療の最新知見】mCRPCの化学療法 タキサン系抗がん剤のエビデンスと使用方法. 泌尿器外科34：945-950, 2021.
-
20. 田畑 健一, 前立腺癌の外科治療 転移のある症例に対する前立腺全摘の意義. Prostate Journal 8：88-93, 2021
-
21. 田畑 健一, 骨転移に対する放射線治療. 泌尿器外科 35：39-44, 2022
-
22. 田畑 健一, PARP阻害薬治療の実際. ESPOIR 5：21-27, 2022
